(Reuters) – The U.S. Food and Drug Administration has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings during an inspection of a contract manufacturer, the company said on Monday.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
